The biotechnology firm previously reached a $60 billion valuation and was on track to rival the scale of Vertex Pharmaceuticals. Much of that historical ascent relied on strong commercial sales of Amvuttra, an established treatment for cardiomyopathy. However, mounting concerns tied to the heart medication now pose a significant hurdle to achieving the targeted $100 billion benchmark.
Key points
Emerging complications with its heart medication are currently hindering Alnylam's pursui…: Emerging complications with its heart medication are currently hindering Alnylam's pursuit of a twelve-figure valuation.
Strong sales of the blockbuster drug Amvuttra remain the primary growth engine for the bi…: Strong sales of the blockbuster drug Amvuttra remain the primary growth engine for the biotechnology firm.
Industry comparisons to peer company Vertex Pharmaceuticals have been disrupted due to on…: Industry comparisons to peer company Vertex Pharmaceuticals have been disrupted due to ongoing drug challenges.
Sources checked by our analysis pipeline: 1
This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.
Accountability check: Let’s talk about my “Alnylam is the next Vertex” take from the Aug. 7, 2025, edition of this newsletter.
Alnylam and Vertex are not direct competitors, but I was intrigued by the possibility that Alnylam’s rapidly accelerating growth — fueled by sales of its blockbuster cardiomyopathy treatment Amvuttra — could push its $60 billion market value equal to or higher than Vertex’s $100 billion market cap in the near future.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Strong consumer demand for extended-range electric variants is shaping the manufacturing strategy for the revived American automaker ahead of its commercial launch. Slower EV adoption across the broader industry prompted the Volkswagen-backed brand to pivot toward hybrid technology featuring engine backup generators. Establishing solid sales conversions from these early commitments will be critical to sustaining operational momentum before deliveries commence.
The semiconductor giant relies on a ten-member leadership team deeply anchored by multi-decade relationships with Chief Executive Officer Jensen Huang. This governance structure unites trusted advisers from the legal, financial, and educational sectors to help steer corporate strategy. The long-standing personal and professional ties ensure continuity as the company navigates its ongoing industry expansion.
Massive sell-offs have erased substantial market value from the artificial intelligence chipmaker amid escalating geopolitical and corporate fallout surrounding its top leadership. Revelations linking Jensen Huang to a suspected Chinese intelligence operative have triggered urgent concerns over the security of vital technological infrastructure. The crisis highlights severe vulnerabilities at the semiconductor giant, where intertwined family ties and governance gaps leave leadership succession in question.